MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

95.54
-0.28
-0.29%
Opening 13:29 10/22 EDT
OPEN
96.48
PREV CLOSE
95.82
HIGH
97.50
LOW
95.40
VOLUME
356.60K
TURNOVER
--
52 WEEK HIGH
136.27
52 WEEK LOW
72.14
MARKET CAP
8.91B
P/E (TTM)
45.37
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
New Strong Sell Stocks for October 19th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 3d ago
Is Neurocrine Biosciences (NASDAQ:NBIX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 10/15 15:45
Baird keeps upbeat outlook on this gene therapy company despite FDA hurdle
Voyager Therapeutics tumbled after-hours yesterday and fell as much as 9.3% today after its Huntington's disease treatment was put on clinical hold - but rallied to close slightly higher today,
Seekingalpha · 10/13 23:28
Neurocrine Biosciences, Xenon Pharmaceuticals Provide Regulatory Update On Ongoing Collaboration To Develop First-In-Class Treatment For Epilepsy; Says FDA Grants Rare Pediatric Disease Designation For NBI-921352 For Treatment Of SCN8A-DEE
-Reuters
Reuters · 10/08 14:02
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients FDA Grants Rare Pediatric Disease Designation for NBI-921352 for the Treatment of SCN8A-DEESAN DIEGO
GlobeNewswire · 10/08 13:00
Neurocrine Biosciences And Xenon Pharmaceuticals Report FDA Is Requesting Additional Non-clinical Data To Support Dose Justification In Pediatric Study Of NBI-921352
U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352
Benzinga · 10/08 12:21
Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments™, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Boston-based Me2/Orchestra, the world's only known classical music organization created for people with mental illness and the people that support them, today announced that they have teamed up with the mental health advocacy community to launch Monumental
PR Newswire · 10/07 10:45
Spruce Biosciences Proposes $75 Million IPO Terms
Spruce Biosciences has filed to raise $75 million in an IPO.The firm is developing treatments for rare endocrine disorders.Early trial results have been impressive and the IPO appears reasonably priced, so is worth a look for long-term hold life science investors.
Seekingalpha · 10/06 20:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBIX. Analyze the recent business situations of Neurocrine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 25 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBIX stock price target is 138.62 with a high estimate of 161.00 and a low estimate of 105.00.
EPS
Institutional Holdings
Institutions: 557
Institutional Holdings: 101.70M
% Owned: 109.05%
Shares Outstanding: 93.25M
TypeInstitutionsShares
Increased
169
7.32M
New
120
406.18K
Decreased
109
7.25M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/Independent Director
William Rastetter
Chief Executive Officer/Director
Kevin Gorman
Chief Financial Officer
Matt Abernethy
Chief Financial Officer
Matthew Abernethy
Chief Human Resource Officer
Julie Cooke
Other
Eric Benevich
Other
David Boyer
Other
Haig Bozigian
Other
Kyle Gano
Other
Dimitri Grigoriadis
Other
Malcolm Lloyd-Smith
Other
Eiry Roberts
Independent Director
.. ..
Secretary
Darin Lippoldt
Independent Director
Gary Lyons
Independent Director
George Morrow
Independent Director
Leslie Norwalk
Independent Director
Richard Pops
Independent Director
Shalini Sharp
Independent Director
Stephen Sherwin
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NBIX
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.